Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO ...

Kenvue (KVUE), the company behind Tylenol and Neutrogena, announced that Thibaut Mongon had left the company, naming Kirk ...

KENVUE Hedge Fund Activity. We have seen 533 institutional investors add shares of KENVUE stock to their portfolio, and 492 decrease their positions in their most recent quarter.

View the latest Kenvue Inc. (1KVUE) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Kenvue stock trades for about 18 times the per-share earnings expected for 2026, compared with the multiple of 21 for its consumer healthcare peers. At a price/earnings ratio of 21, ...

Present Market Standing of Kenvue Trading volume stands at 5,028,386, with KVUE's price down by -1.6%, positioned at $23.11. RSI indicators show the stock to be may be approaching overbought ...

Shares of Kenvue Inc. KVUE advanced 1.53% to $23.96 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.63% to 5,604.14 ...

Shares of Kenvue Inc. KVUE shed 2.08% to $23.50 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the Dow Jones Industrial Average DJIA remaining ...

In a report released today, Anna Lizzul from Bank of America Securities reiterated a Buy rating on Kenvue, Inc. (KVUE – Research Report), with a price target of $25.00. The company’s shares ...

Kenvue faces demand weakness, retailer destocking, and price cuts, raising concerns about structural issues and recovery. Learn more on KVUE stock here.

In my view, Kenvue presented acceptably solid results for 2024. Check out my options-based strategy for KVUE stock that includes short calls and short puts.

In a report released today, Lauren Lieberman from Barclays maintained a Hold rating on Kenvue, Inc. (KVUE – Research Report), with a price target of $23.00. The company’s shares closed ...